<p>Shattuck Labs, Inc.（纳斯达克代码：STTK - 获取免费报告）在覆盖该股票的六家券商中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位投资分析师给予该股票卖出评级，两位给予持有评级，两位给予买入评级，还有一位给予强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 3.00 美元。</p>
<p>STTK 最近成为多份分析师报告的主题。Needham &amp; Company LLC 在 8 月 14 日的研究报告中重新发布了对 Shattuck Labs 股票的 “持有” 评级。华尔街禅在 9 月 13 日的报告中将 Shattuck Labs 的评级从 “卖出” 上调至 “持有”。Leerink Partners 在 8 月 14 日的研究报告中将 Shattuck Labs 的目标价从 4.00 美元下调至 2.00 美元，并对该股票设定了 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Shattuck Labs 股票的 “卖出（d-）” 评级。最后，Wedbush 在 9 月 8 日的研究报告中开始覆盖 Shattuck Labs 股票。他们对该公司的评级为 “跑赢大盘”，目标价为 4.00 美元。</p>
<p>获取 <strong>Shattuck Labs</strong> 的提醒：</p>
<p><strong>查看我们对 STTK 的最新分析</strong></p>
<h2>Shattuck Labs 股价上涨 5.2%</h2>
<p>纳斯达克 STTK 周五开盘价为 2.03 美元。Shattuck Labs 的一年低点为 0.69 美元，一年高点为 2.71 美元。该公司的 50 日移动平均价为 2.06 美元，200 日移动平均价为 1.37 美元。该公司的市值为 1.2846 亿美元，市盈率为-1.99，贝塔值为 1.88。</p>
<p>Shattuck Labs（纳斯达克：STTK - 获取免费报告）最近一次公布财报是在 11 月 6 日，报告显示该季度每股收益为（0.14）美元，超出市场共识预期的（0.15）美元 0.01 美元。该季度的营业收入为 100 万美元。分析师平均预测 Shattuck Labs 本年度每股收益为-1.48 美元。</p>
<h2>Shattuck Labs 的内部活动</h2>
<p>在相关消息中，董事 Mona Ashiya 于 8 月 25 日购买了 6,306,127 股该股票，交易发生在该日。股票的平均购买价格为每股 0.87 美元，总价值为 5,486,330.49 美元。收购完成后，该董事直接持有该公司 5,255,106 股，价值约为 4,571,942.22 美元。此交易代表其持股比例增加了 600.00%。该收购在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，董事 Orbimed Advisors Llc 也于 8 月 25 日购买了 6,306,127 股该公司的股票，平均购买价格为每股 0.87 美元，总价值为 5,486,330.49 美元。交易完成后，该董事直接持有该公司 5,255,106 股，价值为 4,571,942.22 美元。此交易同样代表其持股比例增加了 600.00%。该购买的 SEC 文件提供了更多信息。12.00% 的股票由公司内部人士持有。</p>
<h2>对 Shattuck Labs 的对冲基金看法</h2>
<p>几家大型投资者最近对 STTK 的持仓进行了调整。Turtle Creek Wealth Advisors LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值约为 29,000 美元。Virtu Financial LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值 38,000 美元。AQR Capital Management LLC 在第一季度将其在 Shattuck Labs 的持仓增加了 265.4%。AQR Capital Management LLC 目前持有该公司 43,169 股股票，价值 41,000 美元，此前在该期间内又购买了 31,355 股。Qube Research &amp; Technologies Ltd 在第二季度获得了 Shattuck Labs 的新头寸，价值约为 44,000 美元。最后，Squarepoint Ops LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值 46,000 美元。机构投资者和对冲基金持有该公司 58.74% 的股票。</p>
<h2>关于 Shattuck Labs</h2>
<p>（获取免费报告）</p>
<p>Shattuck Labs, Inc. 是一家临床阶段的生物技术公司，专注于开发用于治疗癌症和自身免疫疾病的疗法。该公司的主要产品候选药物是 SL-172154，目前正在进行卵巢癌、输卵管癌和腹膜癌的第一阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Shattuck Labs</li>
<li>3 只 REIT 值得长期投资</li>
<li>一项伟大的 AI 投资？Stanley Druckenmiller 最新的科技动态</li>
<li>股息贵族的最佳名单：通过贵族指数积累财富</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标价——他们预见了什么</li>
<li>金融服务股票投资</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Shattuck Labs 吗？</h2>
<p>在考虑 Shattuck Labs 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Shattuck Labs 并不在名单上。</p>
<p>虽然 Shattuck Labs 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

STTK

<p>Shattuck Labs, Inc.（纳斯达克代码：STTK）获得了六家券商的共识 “适度买入” 评级。分析师的意见各不相同，评级范围从卖出到强烈买入不等。平均目标价格为 3.00 美元。近期内部人士的购买和对冲基金的活动表明市场对该股票的兴趣。Shattuck Labs 是一家临床阶段的生物技术公司，专注于癌症和自身免疫治疗，其主要候选药物正在进行第一阶段临床试验</p>

<p>Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has earned a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.00.</p>
<div class="lb-trans"><p>Shattuck Labs, Inc.（纳斯达克代码：STTK - 获取免费报告）在覆盖该股票的六家券商中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位投资分析师给予该股票卖出评级，两位给予持有评级，两位给予买入评级，还有一位给予强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 3.00 美元。</p>
</div><p>STTK has been the topic of a number of recent analyst reports. Needham &amp; Company LLC reissued a &#34;hold&#34; rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, September 13th. Leerink Partners reduced their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 14th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, Wedbush assumed coverage on shares of Shattuck Labs in a research report on Monday, September 8th. They issued an &#34;outperform&#34; rating and a $4.00 price objective for the company.</p>
<div class="lb-trans"><p>STTK 最近成为多份分析师报告的主题。Needham &amp; Company LLC 在 8 月 14 日的研究报告中重新发布了对 Shattuck Labs 股票的 “持有” 评级。华尔街禅在 9 月 13 日的报告中将 Shattuck Labs 的评级从 “卖出” 上调至 “持有”。Leerink Partners 在 8 月 14 日的研究报告中将 Shattuck Labs 的目标价从 4.00 美元下调至 2.00 美元，并对该股票设定了 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Shattuck Labs 股票的 “卖出（d-）” 评级。最后，Wedbush 在 9 月 8 日的研究报告中开始覆盖 Shattuck Labs 股票。他们对该公司的评级为 “跑赢大盘”，目标价为 4.00 美元。</p>
</div><p>Get <strong>Shattuck Labs</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Shattuck Labs</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Analysis on STTK</strong></p>
<div class="lb-trans"><p><strong>查看我们对 STTK 的最新分析</strong></p>
</div><h2>Shattuck Labs Trading Up 5.2%</h2>
<div class="lb-trans"><h2>Shattuck Labs 股价上涨 5.2%</h2>
</div><p>NASDAQ STTK opened at $2.03 on Friday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $2.71. The company has a 50 day moving average of $2.06 and a 200-day moving average of $1.37. The firm has a market cap of $128.46 million, a price-to-earnings ratio of -1.99 and a beta of 1.88.</p>
<div class="lb-trans"><p>纳斯达克 STTK 周五开盘价为 2.03 美元。Shattuck Labs 的一年低点为 0.69 美元，一年高点为 2.71 美元。该公司的 50 日移动平均价为 2.06 美元，200 日移动平均价为 1.37 美元。该公司的市值为 1.2846 亿美元，市盈率为-1.99，贝塔值为 1.88。</p>
</div><p>Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $1.00 million during the quarter. On average, analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Shattuck Labs（纳斯达克：STTK - 获取免费报告）最近一次公布财报是在 11 月 6 日，报告显示该季度每股收益为（0.14）美元，超出市场共识预期的（0.15）美元 0.01 美元。该季度的营业收入为 100 万美元。分析师平均预测 Shattuck Labs 本年度每股收益为-1.48 美元。</p>
</div><h2>Insider Activity at Shattuck Labs</h2>
<div class="lb-trans"><h2>Shattuck Labs 的内部活动</h2>
</div><p>In related news, Director Mona Ashiya purchased 6,306,127 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.00% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Mona Ashiya 于 8 月 25 日购买了 6,306,127 股该股票，交易发生在该日。股票的平均购买价格为每股 0.87 美元，总价值为 5,486,330.49 美元。收购完成后，该董事直接持有该公司 5,255,106 股，价值约为 4,571,942.22 美元。此交易代表其持股比例增加了 600.00%。该收购在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，董事 Orbimed Advisors Llc 也于 8 月 25 日购买了 6,306,127 股该公司的股票，平均购买价格为每股 0.87 美元，总价值为 5,486,330.49 美元。交易完成后，该董事直接持有该公司 5,255,106 股，价值为 4,571,942.22 美元。此交易同样代表其持股比例增加了 600.00%。该购买的 SEC 文件提供了更多信息。12.00% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Shattuck Labs</h2>
<div class="lb-trans"><h2>对 Shattuck Labs 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs in the third quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in Shattuck Labs in the 3rd quarter worth $38,000. AQR Capital Management LLC boosted its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after buying an additional 31,355 shares during the period. Qube Research &amp; Technologies Ltd acquired a new position in Shattuck Labs during the 2nd quarter worth approximately $44,000. Finally, Squarepoint Ops LLC acquired a new position in Shattuck Labs during the third quarter worth $46,000. Institutional investors and hedge funds own 58.74% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对 STTK 的持仓进行了调整。Turtle Creek Wealth Advisors LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值约为 29,000 美元。Virtu Financial LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值 38,000 美元。AQR Capital Management LLC 在第一季度将其在 Shattuck Labs 的持仓增加了 265.4%。AQR Capital Management LLC 目前持有该公司 43,169 股股票，价值 41,000 美元，此前在该期间内又购买了 31,355 股。Qube Research &amp; Technologies Ltd 在第二季度获得了 Shattuck Labs 的新头寸，价值约为 44,000 美元。最后，Squarepoint Ops LLC 在第三季度获得了 Shattuck Labs 的新头寸，价值 46,000 美元。机构投资者和对冲基金持有该公司 58.74% 的股票。</p>
</div><h2>About Shattuck Labs</h2>
<div class="lb-trans"><h2>关于 Shattuck Labs</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.</p>
<div class="lb-trans"><p>Shattuck Labs, Inc. 是一家临床阶段的生物技术公司，专注于开发用于治疗癌症和自身免疫疾病的疗法。该公司的主要产品候选药物是 SL-172154，目前正在进行卵巢癌、输卵管癌和腹膜癌的第一阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Shattuck Labs</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>Financial Services Stocks Investing</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Shattuck Labs</li>
<li>3 只 REIT 值得长期投资</li>
<li>一项伟大的 AI 投资？Stanley Druckenmiller 最新的科技动态</li>
<li>股息贵族的最佳名单：通过贵族指数积累财富</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标价——他们预见了什么</li>
<li>金融服务股票投资</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RUSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=STTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Shattuck Labs Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Shattuck Labs 吗？</h2>
</div><p>Before you consider Shattuck Labs, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Shattuck Labs 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Shattuck Labs 并不在名单上。</p>
</div><p>While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Shattuck Labs 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Shattuck Labs, Inc.（NASDAQ:STTK）被分析师一致推荐为 “适度买入”